Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 5/20 | 0.44 |
| ▸ | THRB | P10828 | 5/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 3/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.31 |
| ▸ | ULK1 | O75385 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5434120 | 0.89 | THRA (0.40) | THRATHRBS1PR1S1PR4S1PR5 | |
| SCHEMBL5439867 | 0.89 | THRA (0.47) | THRATHRBS1PR1S1PR4S1PR5 | |
| SCHEMBL5431258 | 0.87 | THRA (0.45) | THRATHRBS1PR1S1PR4S1PR5 | |
| SCHEMBL5417731 | 0.86 | THRA (0.44) | THRATHRBS1PR1S1PR4S1PR5 | |
| SCHEMBL5431255 | 0.82 | THRA (0.42) | THRATHRBS1PR1S1PR4S1PR5 | |
| SCHEMBL4721050 | 0.82 | NPC1 (0.40) | THRATHRBS1PR1S1PR4S1PR5 | |
| SCHEMBL5418924 | 0.80 | RAB9A (0.40) | THRATHRBS1PR1S1PR4S1PR5 | |
| SCHEMBL5418974 | 0.79 | THRA (0.43) | THRATHRBS1PR1S1PR4S1PR5 | |
| SCHEMBL4655588 | 0.79 | UCHL1 (0.39) | THRATHRBS1PR1S1PR4S1PR5 | |
| SCHEMBL5422656 | 0.78 | THRA (0.42) | THRATHRBS1PR1S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | EIF2AK2, BCAT1, IL4I1 | THRA 4325/4885THRB 4066/4885S1PR1 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.